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INTRODUCTION {#s1}
============

In the past few decades, non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of chronic liver disease among adults and children in developed countries.^[@R1]^ It includes a wide range of diseases that are associated with the excessive accumulation of fat (triglycerides) in the liver of people who do not abuse alcohol. It is also accompanied by necrosis, inflammation, and sometimes fibrosis.^[@R1],[@R2]^The global prevalence of NAFLD varies between 2.8% and 46%.^[@R3]^ In Iran, its prevalence is estimated from 21.5% to 31.5%. Comorbid symptoms such as fatigue and pain negatively affect the quality of life. The high prevalence of this chronic, incurable disease imposes an economic burden on the society.^[@R4]^

The pathogenesis of the disease is based on insulin resistance, oxidative stress, and pro-inflammatory cytokines.^[@R5]-[@R7]^ The development of hepatic steatosis is a result of increased flow of free fatty acids in the liver, reduced fatty acid beta-oxidation, and reduced secretion of triglyceride-rich lipoproteins, which are the consequences of insulin resistance.^[@R8]^ Currently, new studies have identified other factors in the pathogenesis of NAFLD. The effect of the gut microbiota is not limited to the gastrointestinal tract and it has been recently reported that NAFLD may be associated with small intestinal bacterial overgrowth.^[@R9],[@R10]^ The interaction between gut microbiota and NAFLD is supported by five mechanisms: 1) Increased ethanol production by intestinal bacteria, 2) increased metabolism of dietary choline and its deficiency (required for the synthesis of very low density lipoprotein \[VLDL\] and liver lipid removal), 3) release of lipopolysaccharide (LPS), 4) regulation of bile acid metabolism and FXR(Farnesoid X Receptor) signaling, and 5) increased obesity by improving the energy efficiency of food and increased fat storage. LPS, like ethanol, stimulates the production of inflammatory cytokines through a mechanism dependent on NF-kβ(Nuclear Factor- kβ). Alteration of gut microbiota leads to increased intestinal permeability, endotoxemia, inflammation, and metabolic disorders.^[@R9],[@R11]^ According to various studies, several factors affect the intestinal immune system, including probiotics (live microorganisms) and prebiotics (food ingredients).^[@R12],[@R13]^ Modification of microbial population (through the use of probiotics and prebiotics) can reduce obesity and body fat by decreasing intestinal permeability and eliminating endotoxemia. Furthermore, the growth of Bifidobacterium improves glucose sensitivity and decreases the production of pro-inflammatory mediators.^[@R14],[@R15]^ Thus, the modification of microbial population can reverse metabolic disorders associated with small intestinal bacterial overgrowth.^[@R16]^

The objective of the present study was to assess the effects of probiotic and prebiotic supplementation on adipokines and insulin resistance in patients with NAFLD. Several studies have evaluated the effects of prebiotic supplementation on biochemical parameters associated with obesity, glucose intolerance, dyslipidemia, and inflammatory diseases.^[@R17],[@R18]^ In just one study with a small sample size (n = 7), prebiotic supplementation effects were studied in NAFLD.^[@R8]^ Previous studies have reported the effects in experimental models or diseases other than fatty liver. In addition, the effect of probiotic and prebiotic consumption on adipokines and glycemic parameters has not been assessed in patients with NAFLD, lending further importance to this study's objective. Therefore, based on the efficacy of prebiotic supplementation for weight and body fat percentage^[@R19]^, insulin resistance, and improved dyslipidemia, we hypothesized that prebiotic supplementation would have a beneficial effect on these parameters in patients with NAFLD.

MATERIALS AND METHODS {#s2}
=====================

Patients {#s2-0-1}
--------

Eligible patients referring to Be'sat Clinic, Kerman, Iran, participated in this study from January 2015 to December 2015. The study was explained to the patients and written informed consent was obtained. The study protocol was approved by the Ethics Committee of Iran University of Medical Sciences (No. 93-03-27-24996). The patients were 20 - 60 years old and NAFLD diagnosis was based on high levels of alanine aminotransferase (ALT \> 1.5 × upper limit of normal) and steatosis on ultrasonography (greater than grade II).^[@R20]^ Other inclusion criteria were: body mass index ≥ 25 kg/m^2^ and ≤ 40 kg/m^2^ and no history of weight loss surgery in the past year and weight loss in the last 3 months. The exclusion criteria were pregnancy, lactation, consumption of ω-3 fatty acids and nutritional supplements in the previous year, having other chronic and acute disorders of the liver (hepatitis B, C, etc.), cirrhosis, celiac disease, diabetes, hypertension, cardiovascular disease, kidney disease, lung disease, alcohol abuse, use of antibiotics over a week during the study, contraceptives pills, corticosteroids, NSAIDs, and other drugs, and also significant changes in the recommended diet and daily physical activity.

The sample size was determined according to serum insulin levels as a key variable in a previous study among the subjects with NAFLD.^[@R21]^ Considering the confidence level of 95% and 80% power, we needed 30 patients for each group. However, we recruited 35 patients per group to account for the possible dropouts.

Research Design {#s2-0-2}
---------------

Eligible individuals were referred from Be'sat Clinic, Kerman, Iran to participate in the study. Full information on the subject, objectives, and implementation of the study was presented in the briefing. Then, the patients signed an informed consent, completed a demographic questionnaire, and were stratified according to their age and sex. In the present study, the patients were randomly allocated into three groups according to the pre-arranged balanced block randomization to receive either one capsule probiotic plus 8 gr prebiotic placebo (maltodextrin) twice daily, or 8 gr prebiotic powder (ORAFTI P95, BENEO, Belgium) twice daily plus one capsule probiotic placebo or 8 gr prebiotic placebo (maltodextrin) twice per day plus one capsule probiotic placebo for 12 weeks. The placebo was identical in appearance to the relevant supplements. Each probiotic capsule (Webber Naturals, Canada) contained 5 billion of 5 bacterial strains *(Lactobacillus casei*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, *Bifidobacterium longum*, and *Bifidobacterium breve*). The study was double-blind and, because the probiotic capsules and prebiotic powder were not identical, we used a double-dummy technique to blind the patients and the investigators who were assessing them. Compliance was estimated by counting pills and weighing powders. Patients were considered compliant if they consumed more than 90% of the supplements throughout the study in the three groups.

Fasting blood samples were obtained at 8:00 AM after 12-14 hours of fasting at the baseline and end of intervention. The patients completed a food-record questionnaire (two usual days and one weekend day) and international physical activity questionnaire (IPAQ) to measure the intensities of physical activity based on metabolic equivalents (MET) in weeks 0, 4, 8, and 12. In addition, at the beginning and end of the study, anthropometric measures including height (at the baseline), weight, and body fat percentage were measured. The patients' BMI was calculated via dividing weight by height squared (kg/m^2^). Since weight loss and increased physical activity are the main treatment for NAFLD, all the patients were offered the diet and physical activity recommendations according to the Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults from National Institute of Health.^[@R22]^

Laboratory Methods {#s2-0-3}
------------------

Serum was isolated and frozen at -86°C until analysis. Adiponectin and leptin were measured by enzyme-linked immunosorbent assay (ELISA). ELISA kits were obtained from Biovendor, Czech Republic. The intra-assay coefficient of variation for leptin and adiponectin was 4.2% and 3.9%, respectively. The sensitivity for leptin and adiponectin was 0.2 and 26 ng/mL, respectively. Serum insulin levels were determined by ELISA method and Demeditec kit (Germany). The intra-assay coefficient of variation for insulin was 2.6% and the sensitivity of insulin kit was 1.76 µLu/mL. Fasting glucose concentrations were obtained using the GOD/POD method (Pars Azmoun, Iran). All the samples were analyzed in the same batch. Insulin resistance (HOMA-IR) was calculated using the following formula^[@R23]^: *\[FBS (mg/dL)×fasting insulin (μU/mL)\]*/405. Also, quantitative insulin-sensitivity check index (QUICKI) was calculated to show insulin sensitivity by the below formula ^[@R24]^: 1/ *\[log Fasting insulin (μU/mL) + log Fasting glucose(mg/dL)\]*

Statistical Analysis {#s2-0-4}
--------------------

Collected information by food-record questionnaire was analyzed in the Nutritionist 4 software modified for Iranian foods. Kolmogorov-Smirnov test was used to verify the normal distribution. Analysis of data was performed using SPSS software version 21 for Windows (SPSS Inc, Chicago, IL, USA). To detect differences in metabolic characteristics and to determine the effect of probiotic capsule and oligofructose powder on some adipokines and glycemic parameters among the three groups, one-way analysis of variance (ANOVA) with Bonferroni post hoc was used. We adjusted all analysis for baseline values using analysis of covariance (ANCOVA). Comparison between the variables was performed by paired t test at the beginning and end of the study in each group. The tests were two-sided and P value of less than 0.05 was considered as statistically significant.

RESULTS {#s3}
=======

89 out of the 111 patients completed 12 weeks of the study and had blood measurements at baseline and after 12 weeks. In the probiotic group, one patient was lost due to non-compliance and five patients were lost to follow-up. In the prebiotic group, six patients were lost to follow-up, one withdrew because of rhinoplasty surgery, three were excluded because of travel, and two refused to give blood after the intervention. In the placebo group, one patient was excluded due to pregnancy and three were lost to follow-up. Therefore, the results obtained with 30 patients in the probiotic group, 29 patients in prebiotic group, and 30 patients in placebo groups. No serious adverse reactions were reported after consumption of the probiotic and prebiotic supplementation in the patients with NAFLD throughout the study. The compliance for probiotic, prebiotic, and placebo groups was 96.5%, 95.5%, and 96% respectively. As shown in [table 1](#T1){ref-type="table"}, there were no significant differences in body mass index, weight, body fat percentage, age, and sex among the groups at baseline ([table 1](#T1){ref-type="table"}).

###### Personal characteristics and body measurements in the intervention and placebo groups at the beginning

  --------------------- ---------------------- ---------------------- -------------------- ---------------------
  **Variables**         **Probiotic (n=30)**   **Prebiotic (n=29)**   **Placebo (n=30)**   ***P*** **value\***
  Age (y)               38.46 ± 7.11           38.41 ± 9.21           38.43 ± 10.09        ns
  Sex (number %)                                                                           ns
  Male                  22 (73.3%)             20 (69%)               21 (70%)             
  Female                8 (26.7%)              9 (31%)                9 (30%)              
  Weight (kg)           84.98±11.75            89.16±12.69            90.65±14.78          ns
  BMI (kg/m^2^)         29.56±2.54             30.81±4.74             31.90±5.04           ns
  Body fat percentage   30.23±5.33             31.38±6.64             32.18±6.41           ns
  --------------------- ---------------------- ---------------------- -------------------- ---------------------

Values are reported as mean±SD.

\* Obtained from the ANOVA test for comparison of data among the intervention and placebo groups.

Ns: not significant.

Weight, body fat percentage, body mass index, physical activity, and energy intake are shown in [table 2](#T2){ref-type="table"}. There was a significant difference between the value of these variables at the beginning and end of the intervention within each group, but these changes were not significant between the three studied groups ([table 2](#T2){ref-type="table"}).

###### Anthropometric measurements and physical activity at baseline and after 12 weeks

  --------------- ------------------- -------------- -------------- --------------------- -----------------------
  **Parameter**   **Studied group**   **Week 0**     **Week 12**    ***P*** **value\***   ***P*** **value\*\***
  Weight (Kg)     Probiotic           84.98±11.7     80.32±10.8     \< 0.001              0.104
  Prebiotic       89.16±12.6          84.76±11.9     \< 0.001                             
  Placebo         90.65±14.7          87.36±15.1     \< 0.001                             
  BFP             Probiotic           30.23±5.3      28.1±5.2       \< 0.001              0.190
  Prebiotic       31.38±6.6           29.25±6.9      \< 0.001                             
  Placebo         32.18±6.4           30.94±5.9      0.007                                
  BMI (Kg/m^2^)   Probiotic           29.56±2.5      27.98±2.4      \< 0.001              0.081
  Prebiotic       30.81±4.7           29.31±4.7      \< 0.001                             
  Placebo         31.9±5.04           30.66±4.7      \< 0.001                             
  Energy (Kcal)   Probiotic           2388.8±542.4   1854.1±379.7   \< 0.001              0.798
  Prebiotic       2527.9±681.7        1917.2±384.6   \< 0.001                             
  Placebo         2417.1±706.5        1909.9±422.1   \< 0.001                             
  MET (m/d)       Probiotic           231.3±265.3    727±446.4      \< 0.001              0.604
  Prebiotic       272.5±320.1         641.6±297.6    \< 0.001                             
  Placebo         283.2±418.2         769.3±664.7    0.001                                
  --------------- ------------------- -------------- -------------- --------------------- -----------------------

Values are reported as mean ± SD.

\*Obtained from the paired samples t test for comparison of data between the beginning and end of the study.

\*\*Obtained from ANCOVA test adjusted for the baseline values among the intervention and placebo groups.

BFP: body fat percentage, BMI: body mass index, MET: metabolic equivalent

According to the data shown in [table 3](#T3){ref-type="table"}, leptin, insulin, and HOMA-IR concentrations decreased significantly in the probiotic and prebiotic groups at the end of week 12 compared with the baseline (leptin: *p* \< 0.001 in both intervention groups, insulin: *p* \< 0.01 in probiotic group, and *p* \< 0.001 in prebiotic group, and HOMA-IR: *p* \< 0.05 in probiotic group and *p* \< 0.01 in prebiotic group) and also among the groups after the treatment (*p* \< 0.001, *p* \< 0.01, and *p* \< 0.05, respectively). Serum concentrations of FBS and adiponectin did not change significantly based on ANCOVA (*p* = 0.296 and *p* = 0.837, respectively). But, adiponectin increased significantly in all groups (*p* \< 0.01). Fasting blood glucose levels showed no significant difference in the placebo and probiotic groups at the end of the study, but there was a significant reduction in the prebiotic group (*p* \< 0.05). QUICKI increased significantly in prebiotic and probiotic groups at the end of the study and among the three groups (*p* = 0.001).

###### Adipokines and glycemic parameters before and after intervention

  --------------------- ---------------------- ---------------- ---------------------- ---------------- -------------------- ---------------- ------------------ --------
  **Parameter**         **Probiotic (n=30)**   ***P*** **\***   **Prebiotic (n=29)**   ***P*** **\***   **Placebo (n=30)**   ***P*** **\***   ***P*** **\*\***   

  Leptin\               Before                 73.10±26.78      \< 0.001               80.34±29.71      \< 0.001             75.85±26.96      0.629              0.000†
  (ng/mL)                                                                                                                                                        

                                                                                                                                                                 

  After                 48.6±13.56             56.86±22.83      74.41±26.17                                                                                      

  Adiponectin (µg/mL)   Before                 24.36±11.11      \< 0.001               27.82±10.43      \< 0.001             25.78±9.45       0.005              0.837

                                                                                                                                                                 

  After                 40.73±24.14            43.9±15.66       39.37±24.17                                                                                      

  FBS                   Before                 91.47±9.86       0.349                  95.31±17.67      0.026                98.3±24.16       0.368              0.296

                                                                                                                                                                 

  After                 88.83±10.14            89.41±16.76      96.23±20.62                                                                                      

  Insulin\              Before                 16.7±8.72        0.004                  15.06±6.26       \< 0.001             17.44±11.66      0.382              0.004†
  (µ IU/mL)                                                                                                                                                      

                                                                                                                                                                 

  After                 12.92±9.32             11.42±4.50       18.49±12.76                                                                                      

  HOMA-IR               Before                 3.82±2.14        0.01                   3.62±1.89        \< 0.001             4.7±5.87         0.959              0.026†

                                                                                                                                                                 

  After                 2.96±2.53              2.58±1.35        4.8±5.45                                                                                         

  QUICKI                Before                 0.32±0.024       0.001                  0.32±0.021       \< 0.001             0.31±0.024       0.614              0.000†

                                                                                                                                                                 

  After                 0.33±0.031             0.34±0.023       0.31±0.022                                                                                       
  --------------------- ---------------------- ---------------- ---------------------- ---------------- -------------------- ---------------- ------------------ --------

Values are reported as mean±SD.

P\*: Obtained from the paired samples t test for comparison of data between the beginning and end of the study.

P\*\*: Obtained from ANCOVA test adjusted for the baseline values among the intervention and placebo groups.

†: Significant difference between probiotic and prebiotic groups with placebo group that obtained from Bonferoni post hoc

DISCUSSION {#s4}
==========

Based on our review of the literature, this study was the first randomized, double-blind clinical trial that investigated the effect of prebiotic and probiotic supplementation on the level of adipokines including leptin and adiponectin, and glycemic parameters in the patients with NAFLD in conjunction with lifestyle modification (diet and exercise recommendations). The current study demonstrated that administration of probiotic and prebiotic among the patients with NAFLD for 12 weeks had beneficial effects on insulin metabolism and serum leptin; however, it did not affect adiponectin and fasting blood sugar compared with the placebo group. Few studies have investigated the effects of probiotics and prebiotics on adipokines such as leptin and adiponectin. In agreement with our study, An and colleagues^[@R25]^ showed the effect of Bifidobacterium *(B. pseudocatenulatum SPM 1204, B. longum SPM 1205, and B. longum SPM 1207)* to reduce circulating leptin in obese mice. Administration of *Lactobacillus plantarum* also reduced serum levels of leptin in Takemura and co-workers' animal study.^[@R26]^ In another work, Parnell and others^[@R27]^ found oligofructose supplementation reduced weight, body fat percentage, fasting glucose, insulin, and leptin levels due to the reduction of adipose tissue in adults with overweight/obesity. In contrast to our study, in Hume's study^[@R28]^ after 16 weeks of supplementation with prebiotic fiber among overweight and obese children, there was a significant increase in adiponectin concentration, while leptin levels did not change between the studied groups.

In one study, Kadooka and colleagues^[@R29]^ used probiotic supplement *(L. gasseri SBT 2055)* to improve obesity and abdominal obesity in adults. *L. gasseri* SBT 2055 supplementation significantly reduced abdominal visceral fat and increased serum adiponectin in obese people. In addition, Kishino and co-workers^[@R30]^ showed that Salacia reticulata supplementation increased the plasma levels of adiponectin in type 2 diabetic rats. In another study, *Lactobacillus plantarum* strain No. 14 reduced white adipose tissue without changing the adiponectin concentration in high fat fed mice.^[@R26]^

The exact mechanisms by which prebiotic and probiotic might influence adipokines concentrations are unknown, but studies suggest that their influence is mediated by changes in the microbiota.^[@R14]^ Lactobacillus stimulates the production of certain cytokines such as TNF-α and, thus, can be effective in regulating the gene expression of leptin.^[@R26],[@R31]^ Furthermore, the production of SCFAs (Short Chain Fatty Acids) during the fermentation of prebiotic fiber may have a positive effect on adiponectin secretion.^[@R32]^ In our study, although in the probiotic and prebiotic groups, the amount of adiponectin increase was larger than that of placebo group, it was not statistically significant possibly because of the effect of lifestyle intervention in each group.

Insulin resistance is a feature of NAFLD and metabolic syndrome. To the best knowledge of the authors, there are no studies that have investigated the effects of probiotic and prebiotic supplementation in one trial. In the current work, HOMA-IR, QUICKI, and serum insulin concentrations were significantly changed in the probiotic and prebiotic groups compared with the baseline levels in the study and placebo groups. Most of the previous studies have shown that treatment with prebiotic or probiotic can control glycemia or decrease serum insulin^[@R33]-[@R37]^, however, some findings are inconsistent.^[@R38]-[@R40]^ In agreement with our study, Daubioul and colleagues^[@R8]^ observed a significant reduction in the insulin concentration following the intake of oligofructose among the patients with NAFLD after 4 weeks. In another study^[@R41]^, the effect of probiotic supplementation on improving glycemic parameters demonstrated a significant decrease in fasting glucose, insulin, and HOMA-IR levels compared with the placebo group. In contrast, Dehghan and co-workers^[@R42]^ showed oligofructose-enriched inulin supplementation reduced fasting blood glucose in the intervention group compared with the placebo. Also, fasting insulin and HOMA-IR were not reduced in the intervention group compared with the placebo. The difference in the results of human studies^[@R42]-[@R44]^, could be related to the differences in the kind of studied diseases, quantity and composition of the basal microbiota population, type of supplements and dosage, basic levels of glycemic parameters, duration of the intervention, and sample size. In the current study, non-significant changes of FBS may be attributed to small sample size.

Possible mechanisms by which prebiotic intake might improve insulin resistance include the adjustment of the energy metabolism, control of obesity, and increased production of GLP-1 and GLP-2 (Glucagon-like peptide 1 and Glucagon-like peptide 2 respectively). GLP-1 moderates pancreatic and plasma insulin secretion, beta cell mass, and its function. Also, GLP-2 enhances insulin sensitivity in the liver, fat, and muscle.^[@R38]^ Probiotics are effective in improving the insulin resistance by reducing the concentration of endotoxin, increasing fecal PH, and reducing the production and absorption of intestinal toxins.^[@R45]^ Thus, modulating gut microbiota can be effective in improving glycemic status through the use of probiotics and prebiotics.

The strengths of this study were the blocked randomization stratified of patients and assessment of adipokines secreted from adipose tissue to assess the effects of probiotic and prebiotic supplementation on the adipose tissue. Also, the participants' disease was re-assessed recently and none of them had received any treatment. The other strength of this study was the comparison of prebiotic and probiotic supplementations effect on the investigated variables. The limitations of this study were the impracticality of assessing liver fibrosis and inflammatory biomarkers at the cellular level due to limited financial resources. Fecal bacteria loads were not quantified before and after the treatment. Also, because of time and budget limitations, there was no possibility of increasing the duration of the intervention, sample size, or investigation of simultaneous prebiotic and probiotic supplementation (synbiotic) in a distinct group. The application of this study is that probiotic and prebiotic supplementation can be recommended as a therapeutic aid for lifestyle modification in the subjects with NAFLD.

CONCLUSION {#s5}
==========

This double-blind randomized controlled clinical trial shows that probiotic and prebiotic supplementation along with lifestyle intervention creates favorable changes in glycemic parameters and leptin levels compared with the lifestyle intervention alone. Also in this study, oligofructose dietary fiber intake was as effective as probiotic supplementation in controlling insulinemia and adipokines, but further studies are needed to confirm this issue.

The present study was supported by a grant from Vice Chancellor for Research, Iran University of Medical Sciences, Tehran, Iran (no. 24996). Thanks are extended to Digestive Research Center (KMU, Kerman, Iran) for their assistance in this project.

Clinical trial registration number: www.irct.ir:IRCT201410052394N13.

**CONFLICT OF INTEREST:** The authors declare no conflict of interest related to this work.
